Multidisciplinary palliation for unresectable recurrent rectal cancer: hypoxic pelvic perfusion with mitomycin C and oxaliplatin in patients progressing after systemic chemotherapy and radiotherapy, a retrospective cohort study Stefano Guadagni et al, 2019, Oncotarget CrossRef
Relevance of Pharmacogenomics and Multidisciplinary Management in a Young-Elderly Patient With KRAS Mutant Colorectal Cancer Treated With First-Line Aflibercept-Containing Chemotherapy Gemma Bruera et al, 2020, Frontiers in Oncology CrossRef
Clinical parameters to guide decision-making in elderly metastatic colorectal cancer patients treated with intensive cytotoxic and anti-angiogenic therapy Gemma Bruera et al, 2017, Oncotarget CrossRef
The prevalent KRAS exon 2 c.35 G>A mutation in metastatic colorectal cancer patients: A biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens? Gemma Bruera et al, 2015, Critical Reviews in Oncology/Hematology CrossRef
Poorly differentiated neuroendocrine rectal carcinoma with uncommon immune-histochemical features and clinical presentation with a subcutaneous metastasis, treated with first line intensive triplet chemotherapy plus bevacizumab FIr-B/FOx regimen: an experience of multidisciplinary management in clinical practice null null et al, 2019, BMC Cancer CrossRef
Toxicity Syndromes, Patient-Related Clinical Indicator of Toxicity Burden Induced by Intensive Triplet Chemotherapy-Based Regimens in Gastrointestinal Cancers With Metastatic Disease Gemma Bruera et al, 2020, Frontiers in Oncology CrossRef
Pharmacogenomic Assessment of Patients with Colorectal Cancer and Potential Treatments
Gemma Bruera et al, 2020, Pharmacogenomics and Personalized Medicine CrossRef
Precision oncotherapy based on liquid biopsies in multidisciplinary treatment of unresectable recurrent rectal cancer: a retrospective cohort study Stefano Guadagni et al, 2020, Journal of Cancer Research and Clinical Oncology CrossRef